The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat

Irish Journal of Medical Science

Volumn 165, Issue 3, 1996, Pages 213-218

  MacIomhair, M ^a   Lavelle, S M ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; PROTHROMBIN; WARFARIN;

ANIMAL MODEL; ANTICOAGULANT THERAPY; AORTA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING; CAVA VEIN; CONTROLLED STUDY; FEMALE; LONG TERM CARE; MALE; NONHUMAN; PROTHROMBIN TIME; RAT; THROMBOSIS; VEIN THROMBOSIS; PRIORITY JOURNAL;

EID: 0029840816     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02940253     Document Type: Article

References (41)

1. Mueller, A. L., Scheidt, S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation 1994; 89: 432-449.
2. Hirsh, J. Oral anticoagulant drugs. N. Engl. J. Med. 1991; 324: 1865-1875.
3. Landefeld, C. S., Rosenblatt, M. J., Goldman, L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am. J. Med. 1989; 87: 153-159.
4. Hull, R. D. Venous thrombosis - treatment and pulmonary embolism. Med. International 1985; 2: 805-812.
5. Sise, H. S., Lavelle, S. M., Adamis, D., Becker, R. Relation of haemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants. N. Engl. J. Med. 1958; 259: 266-271.
6. Quick, A. J. The prothrombin in haemophilia and in obstructive jaundice. J. Biol. Chem. 1935; 109: 73-74.
7. MacIomhair, M., Lavelle, S. M. Thrombus weight as a measure of hypercoagulability induced by drugs. Thromb. Haemostas. 1979; 42: 1018-1021.
8. Lavelle, S. M., MacIomhair, M. The quantitative reduction by heparin of intravenous thrombosis in normal and hypercoagulable animals. Irish J. Med. Sci. 1980; 149: 266-269.
9. Poller, L. The effect of the use of different tissue extracts on one-stage Prothrombin Times. Acta. Haematol. 1964; 32: 292-298.
10. Hjort, P., Rapaport, S. I., Owren, P. A. A simple specific one-stage prothrombin assay using Russell's viper venom in cephalin suspension. J. Lab. Clin. Med. 1955; 46: 89-97.
11. Bachmann, F., Duckert, F., Koller, F. The Stuart-Prower factor assay and its clinical significance. Thromb. Diath. Haemorrh. 1958; 2: 24-38.
12. Hirsh, J., Dalen, J. E., Deykin, D., Poller, L. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992; 102: 312S-326S.
13. Olsen, P. S., Ljungqvist, U., Bergentz, S. E. Thrombus formation in stainless steel tubes used as vascular implants in the dog. Thromb. Res. 1974; 4: 271-283.
14. Mason, R. G., Wolf, R. H., Zucker, W. H., Shinoda, B. A., Mohammad, S. F. Effect of antithrombotic agents evaluated in a nonhuman primate vascular shunt model. Am. J. Pathol. 1976; 83: 557-568.
15. Farced, J., Walenga, J. M., Kumar, A., Rock, A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Sennin. Thromb. Haemost. 1985; 2: 155-175.
16. Shoenfeld, N. A., Yeager, A., Connolly, R., Ramberg, K., Forgione, L., Giorgio, A., Valeri, C. R., Callow, A. D. A new primate model for the study of intravenous thrombotic potential and its modification. J. Vasc. Surg. 1988; 8: 49-54.
17. Sise, H. S., Moschos, C. B., Becker, R. On the nature of hypercoagulability. Am. J. Med. 1962; 33: 667-678.
18. Emms, H., Lewis, G. P. The effect of synthetic ovarian hormones on an in vivo model of thrombosis in the rat. Br. J. Pharmac. 1985; 84: 243-248.
19. Mestre, M., Clairefond, P., Mardiguian, J., Trillou, M., Le Fur, G., Uzan, A. Comparative effects of heparin and PK 10169, a low molecular weight fraction, in a canine model of arterial thrombosis. Thromb. Res. 1985; 38: 389-399.
20. Lavelle, S. M., MacIomhair, M. Arterial thrombosis in rats by platinum wire insertions, ellagic acid and EACA. In: Standardization of animal models of thrombosis. (eds.) Breddin, K., Zimmerman R. pp. 157-160. Schattauer Verlag Stuttgart - New York 1993.
21. Vainieri, H., Wingaard, L. B. Effect of warfarin on the kinetics of vitamin K-dependent clotting factors in rats. J. Pharmacol. Exp. Ther. 1977; 201: 507-517
22. Coon, W. W., Willis, P. W. III Some aspects of the pharmacology of oral anticoagulants. Clin. Pharmacol. Ther. 1970; 11: 312-336.
23. Breckenridge, A. M. Interindividual differences in the response to oral anticoagulants. Drugs 1977; 14: 367-375.
24. Guinan, M. E., Astrup, T. High fibrinolytic activity in the endothelium of the arteries of the rat. Thromb. Res. 1980; 19: 333-338.
25. Cadroy, Y., Horbeet, T. A., Hanson, S. R . Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo. J. Lab. Clin. Med. 1989; 113: 436-448.
26. Newland, H., Norday, A. Effect of large doses of warfarin sodium on haemostasis and on ADP-induced platelet aggregation in vivo in the rat. Cardiovasc. Res. 1967; 1: 362-370.
27. Zivelin, A., Rao, V. M., Rapaport, S. I. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin k-dependent clotting factors. J. Clin. Invest. 1993; 92: 2131-2140.
28. Reyers, I., de Gaetano, G., Donati, M. B. Warfarin anticoagulation prevents experimental arterial thrombosis in rats without inducing haemorrhage. Thromb. Res. 1983; 29: 465-468.
29. Frost, T., Lau, K. S., Jones, K. O. A. The Australasian reference thromboplastin: 1'. A study in bleeding patients. Path. 1981; 13: 525-535.
30. Paul, B., Oxley, A., Brigham, K., Cox, T., Hamilton, P. J. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J. Clin. Pathol. 1987; 40: 94-98.
31. Chan, E., Aarons, L., Serlin, M., Breckenridge, A., Rowland, M. Inter-relationship among individual vitamin k-dependant clotting factors at different levels of anticoagulation. Br. J. Clin. Pharm. 1987; 24: 621-625.
32. Smith, G. F., Neubauer, B. L., Sundboom, J. L., Best, K. L., Goode, R. L., Tanzer, L. R., Merriman, R. L., Frank, J.D., Herrmann, R. G. Correlation of the in vivo anticoagulant, antithrombotic and antimetastatic efficacy of warfarin in the rat. Thromb. Res. 1988; 50: 163-174.
33. Bern, M. M., Lockich, J. J., Wallach, S. R., Boethe, A., Benotti, P. N., Arkin, C. F, Greco, F. A., Huberman, M., Moore, C. Very low doses of warfarin can prevent thrombosis in central venous catheters. An. Intern. Med. 1990; 112: 423-428.
34. Mason, R. G., Wolf, R. H., Zucker, W. H., Shinoda, B. A. Dynamics of thrombus formation on an artificial surface in vivo. Am. J. Pathol. 1976; 82: 445-456.
35. Gitel, S. N., Wessler, S. Dose-dependent antithrombotic effect of warfarin in rabbits. Blood 1983; 61: 435-438.
36. Reyers, I., de Gaetano, G., Donati, M. B . Protective effect of warfarin in arterial thrombosis: evidence from a vascular prosthesis model in rats. Thromb. Haemostas. 1983; 50: 821-823.
37. Petitti, D. B., Strom, B. L., Melmon, K. L. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J. Clin. Epidemiol. 1989; 42: 759-764.
38. Hirsh, J. Therapeutic range for the control of oral anticoagulant therapy. Arch. Intern. Med. 1985; 145: 1187-1188.
39. Ansell, J. E. Imprecision of Prothrombin Time monitoring of oral anticoagulation. Am. J. Clin. Pathol. 1992; 98: 237-239.
40. Hirsh, J. Substandard monitoring of warfarin in north America. Arch. Intern. Med. 1992; 152: 257-258.
41. Bussey, H. I., Force, R. W., Bianco, T. M., Leonard, A. D. Reliance on Prothrombin Time ratios causes significant errors in anticoagulation therapy. Arch. Intern. Med. 1992; 152: 278-282.